Literature DB >> 6511520

Analysis of prognostic variables in hyperthermia treatment of 161 patients.

J R Oleson, D A Sim, M R Manning.   

Abstract

From 1977-1982, 161 patients were treated using hyperthermia as an adjuvant in Phase I trials. Microwave applicators (MW), capacitively coupled plates (RF plates), interstitial localized current fields (LCF), and magnetic induction heating (MI) techniques were used together with radiation in 135 patients, with chemotherapy in 10 patients, and alone in 16 patients. Tumor volume response categories were no response (NR, less than 50% decrease); partial response (PR, 50% less than or equal to volume decrease less than 100%); and complete response (CR, complete disappearance). The CR rates and total response rates (CR + PR) were 38/160 (24%) and 90/160 (56%), respectively. There were highly significant differences among techniques in CR vs PR + NR (p = .001), and in CR + PR vs NR (p less than .0005). Response did not vary significantly with histologic category. Overall toxicity was 16%, and did not vary significantly with technique (p = .193). In the patient group treated with hyperthermia and radiation, multivariate analysis revealed that a set of three variables had prognostic importance for CR: technique (p = .011), radiation dose (p = .019), and tumor volume (p = .001, negatively correlated). A good correlation also existed between CR and the minimum tumor temperature averaged over all treatments, TMIN (p less than .0005). Temperature variables themselves were correlated with tumor volume. Minimum T correlated negatively with volume (p = .017) and TMAX correlated positively with volume (p = .026). In fewer than 50% of patients could minimum T greater than 40.7 degrees C be achieved. Our conclusions are: TMIN, tumor volume, radiation dose, and heating technique have prognostic value for initial response; variation in CR vs technique reflects variation in tumor volume treated and in minimum temperature achieved with these techniques; and acute toxicity of treatment is infrequent, but serious toxicity is possible with the interstitial technique.

Entities:  

Mesh:

Year:  1984        PMID: 6511520     DOI: 10.1016/0360-3016(84)90228-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Thermal dose fractionation affects tumour physiological response.

Authors:  Donald E Thrall; Paolo Maccarini; Paul Stauffer; James Macfall; Marlene Hauck; Stacey Snyder; Beth Case; Keith Linder; Lan Lan; Linda McCall; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2012       Impact factor: 3.914

2.  Radiofrequency capacitive hyperthermia for unresectable hepatic cancers.

Authors:  K Yamamoto; Y Tanaka
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

Review 3.  Hyperthermia for locally advanced breast cancer.

Authors:  Timothy M Zagar; James R Oleson; Zeljko Vujaskovic; Mark W Dewhirst; Oana I Craciunescu; Kimberly L Blackwell; Leonard R Prosnitz; Ellen L Jones
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 4.  Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data.

Authors:  Timothy M Zagar; James R Oleson; Zeljko Vujaskovic; Mark W Dewhirst; Oana I Craciunescu; Kimberly L Blackwell; Leonard R Prosnitz; Ellen L Jones
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

5.  'Patchwork' fields in thermoradiotherapy for extensive chest wall recurrences of breast carcinoma.

Authors:  K Engin; L Tupchong; F M Waterman; L Komarnicky; C M Mansfield; D B Leeper
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

Review 6.  Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment.

Authors:  Adela Ademaj; Danai P Veltsista; Pirus Ghadjar; Dietmar Marder; Eva Oberacker; Oliver J Ott; Peter Wust; Emsad Puric; Roger A Hälg; Susanne Rogers; Stephan Bodis; Rainer Fietkau; Hans Crezee; Oliver Riesterer
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.